October 2023

After COVID windfall, Pfizer turns attention to RSV launch and a potential future in obesity

After COVID windfall, Pfizer turns attention to RSV launch and a potential future in obesity

As COVID revenues dwindle for pandemic stalwart Pfizer, the company is turning attention to its respiratory syncytial virus (RSV) vaccine launch and a potential entry into the hot obesity market. With only five months of sales under its belt, Pfizer’s RSV vaccine Abrysvo is “doing better than we thought,” chief commercial officer Angela Hwang said on the […]

After COVID windfall, Pfizer turns attention to RSV launch and a potential future in obesity Read More »

With Tepezza sales still stagnant, Amgen has a plan to boost the newly acquired TED drug

With Tepezza sales still stagnant, Amgen has a plan to boost the newly acquired TED drug

As Amgen’s $27.8 billion buyout of Horizon Therapeutics became official earlier this month, one of the first orders of business for the California biotech giant was to get acquired blockbuster Tepezza back on track. After generating sales of $1.66 billion in its first full year on the market (2021) and $1.97 billion last year, the

With Tepezza sales still stagnant, Amgen has a plan to boost the newly acquired TED drug Read More »

Battling new rivals and bracing for Jakafi’s patent cliff, Incyte shores up growth plan

Battling new rivals and bracing for Jakafi’s patent cliff, Incyte shores up growth plan

As several new JAK inhibitors threaten Incyte’s bread-and-butter Jakafi in myelofibrosis, the company is busy advancing new regimens ahead of the drug’s 2028 patent cliff. Two recently launched JAK inhibitors “haven’t really moved at all over many quarters” in terms of market share or net sales, Barry Flannelly, Incyte’s North America general manager, said on the company’s

Battling new rivals and bracing for Jakafi’s patent cliff, Incyte shores up growth plan Read More »

As COVID sales crater, Pfizer takes $5.6B in inventory write-offs on Paxlovid, Comirnaty

As COVID sales crater, Pfizer takes $5.6B in inventory write-offs on Paxlovid, Comirnaty

For Pfizer, several years of pandemic megaprofits have soured as overstocked COVID-19 drugs and vaccines take a major toll on the drug behemoth’s financials. In the third quarter of 2023, Pfizer recorded $5.6 billion in coronavirus-related inventory write-offs and other charges, plus a $4.2 billion revenue reversal tied to the planned return of some 7.9

As COVID sales crater, Pfizer takes $5.6B in inventory write-offs on Paxlovid, Comirnaty Read More »

Abbott kicks off new heart health campaign with pro football player Damar Hamlin

Abbott kicks off new heart health campaign with pro football player Damar Hamlin

Medical device giant Abbott is teaming up with Buffalo Bills player Damar Hamlin, who recently suffered from a near fatal cardiac arrest on the field, to boost awareness about heart health. The new “HeartMates” campaign will be fronted by Hamlin, who is Abbott’s first program ambassador. Hamlin’s story is well-known to many Americans. As a safety

Abbott kicks off new heart health campaign with pro football player Damar Hamlin Read More »

Novartis drug candidate scores interim win in rare kidney disease trial – ET HealthWorld | Pharma

Novartis drug candidate scores interim win in rare kidney disease trial – ET HealthWorld | Pharma

Frankfurt: Novartis said its experimental drug atrasentan was shown to have a positive effect on an indicator of kidney health in people suffering from a rare type of kidney disease in an interim analysis of a late-stage drug trial. Treatment with the drug candidate, acquired as part of the purchase of US biotech firm Chinook

Novartis drug candidate scores interim win in rare kidney disease trial – ET HealthWorld | Pharma Read More »

High-performance computing could improve therapy for hard-to-treat cancer

High-performance computing could improve therapy for hard-to-treat cancer

Researchers reduced 4D-MRI image reconstruction times to 60 seconds Researchers at the Institute of Cancer Research (ICR) and the Royal Marsden NHS Foundation Trust have revealed that high-performance computing can facilitate a new radiotherapy approach for hard-to-treat cancers. Using a new high-performance computing method, researchers were able to reduce the time taken

High-performance computing could improve therapy for hard-to-treat cancer Read More »

Scroll to Top